The new GB550 analyzer, which was debuted at American Society For Microbiology 2016, increases potential revenue per instrument by 35% to 40%.

It will enable lab technicians to process tests in 75 to 90 minutes, with the potential for several tests in less than 60 minutes.

The GB550 analyzer, which features a simplified software interface, is compatible with all existing and future Great Basin tests and panels.

It is compatible with company’s tests for Toxigenic Clostridium difficile (C. diff), Group B Streptococcus (GBS), in addition to the newly cleared Shiga toxin direct test and the Staph ID/R blood culture panel.

The analyzer includes an integrated touchscreen and barcode scanner that reduces the overall footprint, as well as eliminates the need for external cables.

Great Basin Scientific co-founder and CEO Ryan Ashton said: "We’re pleased with the ongoing improvements we’ve made to our original instrument and how those efforts have informed the design of the GB550.

"Our customers will enjoy the smaller footprint, improved ease-of-use and reduced test time, which we believe will make our system even more attractive to a wider variety of users that, in turn, will allow us to expand our footprint of installed sites."

The company intends to make the new analyzer available for the customers in the first half of this year.

Great Basin is engaged in the development of chip-based technologies for multiple-pathogen diagnoses of infectious diseases.

Image: Great Basin’s new GB550 molecular diagnostic analyzer. Photo: courtesy of Business Wire.